Imetelstat (GRN163L)

Imetelstat (GRN163L) is a drug being researched for its potential to treat certain types of blood cancers, particularly myelodysplastic syndromes and multiple myeloma. It works as a telomerase inhibitor, which means it targets the enzyme telomerase that helps cancer cells grow and divide by maintaining their telomeres—protective caps on the ends of chromosomes. By inhibiting telomerase, Imetelstat aims to limit the lifespan of cancer cells, ultimately slowing down or stopping tumor growth. Clinical trials are ongoing to determine its safety and effectiveness in patients with these conditions.